S
troke risk is lower in premenopausal women than in men of the same age, but vascular events increase in frequency after menopause. 1 However, the benefit of hormone replacement therapy for stroke is not clearly defined. We have previously shown that female animals sustain less brain injury from middle cerebral artery occlusion (MCAO) than do age-matched male animals and that this advantage is abolished with the loss of endogenous female sex steroids through ovariectomy. 2 Hence, both estrogen and progesterone must be considered as neuroprotective candidates. Ongoing inquiries in various laboratories have been centered on estrogen, yet little is known about progesterone and ischemic injury in the female. Furthermore, current hormone replacement therapy for postmenopausal women incorporates progestin combined with estrogen, so it is important to evaluate the efficacy of progestin compounds in stroke. The purpose of See Editorial Comment, page 1178 the present study was to determine whether there are differences in infarction volume in progesterone-treated, previously ovariectomized female rats compared with hormonedeficient female rats.
Materials and Methods
The present study was conducted in accordance with the National Institutes of Health guidelines for the care and use of animals in research, and the protocols were approved by the Animal Care and Use Committee of the Johns Hopkins University. All methods are as previously described. 2, 3 Briefly, age-matched, sexually mature female Wistar rats (200 to 225 g) were ovariectomized 1 to 2 weeks before progesterone treatments (50 mg/mL progesterone USP; Schein) and MCAO. Ovariectomized female rats received either no hormone (P0, nϭ14), 30 mg/kg progesterone (P30, nϭ14), or 60 mg/kg progesterone (P60, nϭ12) IP 30 minutes before MCAO. In an additional cohort, ovariectomized female rats were administered 30 mg/kg progesterone (chronic P30, nϭ16) IP daily for 7 to 10 days before MCAO. For MCAO, the animal was anesthetized with halothane (1.25% to 1.5% delivered via mask in O 2 -enriched air), and a femoral artery catheter was placed for the continuous monitoring of mean arterial blood pressure and the measurement of arterial blood gases. Rectal and temporalis muscle temperatures were monitored with a Mon-a-therm system (model 6510; Mallinckrodt Medical, Inc) and maintained with a heat lamp. The effectiveness of vascular occlusion was determined by the reduction in the laser Doppler flow signal (LDF) (model MBF3D; Moor Instruments Ltd) obtained with probe placement 6 mm lateral and 2 mm posterior to bregma. 2, 3 Focal cerebral ischemia was accomplished with a modified intraluminal filament technique as previously described. 4 Briefly, the right common carotid and external carotid arteries were exposed and ligated. The right occipital artery was cauterized, and then the right pterygopalatine artery was ligated. After the baseline LDF was determined, a 4 -0 nylon monofilament surgical suture with a heat-blunted tip was introduced via the right common and internal carotid arteries until the LDF signal displayed an abrupt and significant reduction, which confirmed ongoing ischemia. Then, the suture was secured in place. LDF was measured during ischemia for 15-to 30-minute intervals and for the first 15 minutes of reperfusion, which was achieved through withdrawal of the suture. Five-minute recording averages were analyzed for each time point. The animal was killed 22 hours after the 2-hour MCAO period, and the brain was harvested for staining with a 1% solution of 2,3,5-triphenyltetrazolium chloride (Sigma Chemical Co.) and subsequently fixed in 10% neutral buffered formalin. Infarction volumes in cerebral cortex, caudate-putamen complex, and hemisphere were determined with digital image analysis (SigmaScan Pro; Jandel) and expressed either in mm 3 or indirectly as a percent of the contralateral structure (cortex, caudate-putamen, or hemisphere). Indirect infarction volumes were determined through subtraction of the ipsilateral noninfarcted volume of the structure of interest from the volume of the contralateral structure. This value was then divided by the volume of the contralateral structure and multiplied by 100 to yield the infarction volume as a percent of the contralateral structure. Blood was obtained 1 hour into ischemia and at 22 hours' reperfusion for steroid analysis. Plasma 17␤-estradiol and progesterone levels were measured in duplicate with radioimmunoassay (Coat-a-count; Diagnostic Products Corp), as previously described. 5 All values are reported as meanϮSEM unless otherwise indicated. Physiological parameters and LDF were subjected to 2-way ANOVA with post hoc Newman-Keuls test for multiple comparisons. Plasma hormone levels were analyzed with t test with Bonferroni's correction. Differences in mean ischemic LDF, cortical, and hemispheric infarction volumes were determined with 1-way ANOVA. If significant differences were observed with 1-way ANOVA, a post hoc Tukey's test was performed. Striatal infarction volume was analyzed with t test with Bonferroni's correction. The criterion for statistical significance was PϽ0.05.
Results
Baseline, intraischemic, and reperfusion arterial blood pressure and blood gases, glucose, and hemoglobin measurements were equivalent among experimental groups (Table) . However, arterial CO 2 tension was higher at 60-minute MCAO in all progesterone-treated rats and at preischemia and reperfusion in the chronic P30 group relative to the P0 group, although all values remained within normal limits for the rat. Intraischemic rectal and temporalis muscle temperatures were controlled in all groups at 38.1°to 38.8°C and 36.3°to 37.0°C, respectively. Intraischemic plasma estradiol was not different among groups: 0Ϯ0, 0Ϯ0, 1Ϯ1, and 5Ϯ2 pg/mL in P0, P30, P60, and chronic P30 groups, respectively. Progesterone levels were elevated relative to untreated, ovariectomized animals within the ischemic period (Table) but fell by 22 hours of reperfusion: 5Ϯ2, 10Ϯ3, 33Ϯ11, and 8Ϯ1 ng/mL in P0, P30, P60, and chronic P30 groups, respectively. Figure 1 illustrates the lack of effect of progesterone on cortical infarction volume at either acute dose tested compared with the P0 female rats. Similarly, acute treatment did not improve caudate-putamen injury (percent of contralateral caudate-putamen): 29.2Ϯ5.3% for P0 versus 35.8Ϯ5.1% and 
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Discussion
The present study demonstrates 2 important findings. First, exogenous progesterone treatment over a range of physiological and supraphysiological peak plasma levels did not improve brain injury after vascular occlusion in young adult, ovariectomized female rats. Second, chronic hormone exposure at high doses can exacerbate infarction volume after reversible MCAO. These findings suggest that progesterone is not neuroprotective in the ischemic female rat brain when administered as a single injection and that exogenous steroid has a dose-or exposure-dependent, deleterious action in experimental stroke.
Our findings are not explained by differences in physiological parameters among treatment groups. Arterial CO 2 tension was statistically higher at 60-minute MCAO in all progesterone-treated rats and at all time points in the chronic P30 group compared with the P0 group. It seems unlikely that progesterone would increase CO 2 production. However, many members of the progestin neurosteroid family have mild anesthetic properties. It may be possible that progesterone at high doses provided an additional anesthetic effect with halothane inhalation and resulted in a slightly reduced ventilatory rate and thus retained CO 2 . However, these small increases in arterial CO 2 are unlikely to account for the deleterious effect of progesterone on infarction volume due to changes in tissue pH or altered cerebral perfusion. On the contrary, a relative hypercapnia would increase cerebral blood flow, not depress perfusion. Furthermore, the LDF signal was reduced by a similar percentage of baseline values in all groups, suggesting that the ischemic insult was equivalent among all groups. Differences in the recovery of cerebral flow during early reperfusion cannot be excluded with our measurements, and further studies are needed to quantify absolute cerebral blood flow in progesterone-treated animals. Although there is little evidence that progesterone is vasoactive in the cerebral circulation, large doses of the steroid induce in vitro coronary relaxation 6 and enhance endothelium-dependent relaxation to agonists. 7 In the present study, progesterone treatment was associated with a larger infarct in the striatum but no changes in cortical infarct in young ovariectomized female rats. This is in contrast to our previous findings in reproductively senescent female rats, in which progesterone (10 mg) reduced cortical injury 8 and produced no deleterious histological outcome. However, it is not known whether mechanisms of ischemic injury and neuroprotection are similar in young adult versus reproductively senescent female rats. The lack of neuroprotection and exacerbation of striatal injury are also inconsistent with the evidence from the literature that reports beneficial effects of progesterone 9 therapy in young animals. In models of traumatic brain injury, exogenous progesterone (4 mg/kg) in male rats has been shown to reduce secondary neuronal loss and to attenuate brain edema, independent of estrogen, 10 -13 via mechanisms linked to the reduction in free radical-induced lipid peroxidation. 9, 14 In male rats, pretreatment with progesterone significantly reduced brain edema during the early stages of ischemia. 15, 16 The administration of progesterone (4 to 10 mg/kg) before or after the onset of transient focal cerebral ischemia in male rats 17 or of global ischemia in ovariectomized cats 18 greatly reduced ischemic cell damage and neurological deficits. One explanation for the divergence of the present data from previous reports could be linked to the dose and duration of progesterone used, as well as to differential effects linked to gender or age.
Although variations in plasma progesterone reflected individual differences in intraperitoneal absorption and metabolism of the injected drug, the chronic 30 mg/kg progesterone group demonstrated an average plasma progesterone level of 133 ng/mL compared with 102 and 181 ng/mL for the 30 and 60 mg/kg acute progesterone doses, respectively. In rat, plasma progesterone ranges from basal levels of 2 to 18 ng/mL to Ϸ120 to 130 ng/mL in pregnancy, with intermediate values of 40 to 90 ng/mL during late proestrus. 19 -22 The low 30-mg treatment was intended to achieve robust elevation of intraischemic plasma progesterone within the physiological range, whereas the 60 mg/kg injection resulted in pharmacological levels. All treatment groups showed low levels by 22 hours of reperfusion, ranging from 6 to 33 ng/mL on average, or absolute decreases from ischemic levels, ranging from 92 to 148 ng/mL in progesterone treatment groups. Although previous studies in neurotrauma and cerebral ischemia provide only scattered reporting of hormone levels, it is likely that peak levels were lower than in the present study. We therefore cannot rule out the possibility that lower progesterone doses that yield basal plasma levels could be neuroprotective in female rats, as has been shown in male rats. Furthermore, only our chronic dosing regimen resulted in increased striatal injury, suggesting that exposure duration may be important, as well as peak steroid levels. In combination with the data in the literature, the present data suggest that the therapeutic window for progesterone may be narrow in both its efficacious actions 8, 17, 18 and potential for exacerbation of ischemic injury. The mechanism for this exacerbation in not yet known.
It may be that the abrupt and large drop in plasma progesterone from ischemic values to those levels observed at 22 hours of reperfusion mimicked a withdrawal syndrome and contributed to striatal injury. Our previous study in reproductively senescent female rats, which demonstrated cortical protection with progesterone, used long-term steroid delivery via a subcutaneous hormone implant 8 rather than a daily injection protocol. This method of hormone administration ensured sustained plasma progesterone levels during the reperfusion period rather than the declining levels we observed.
In women with premenstrual syndrome, anxiety 23 and increased seizure 24, 25 susceptibility are associated with sharp declines in circulating progesterone levels. Rats undergoing progesterone withdrawal exhibit greater seizure-like activity than do control animals. 26 Abrupt progesterone withdrawal has been shown to markedly decrease ␥-aminobutyric acid (GABA) current decay time, consequently decreasing inhibitory function and increasing seizure susceptibility. 27 The withdrawal of progesterone also increased expression of the GABA A receptor ␣4 subunit. 27 Blockade of the ␣4 gene transcript via antisense oligonucleotide administration prevented the previously observed decreases in GABA current decay time after progesterone withdrawal. 27 It may be that the increase in striatal injury is due to both GABA current modulation and alterations in GABA A receptor ␣4 subunit levels as a result of sharply declining plasma progesterone levels after ischemia. Glutamate also could be a target of hormonal neuromodulation with deleterious consequences. Naturally occurring sulfate esters of pregnenolone have distinct excitatory properties that are due in part to augmentation of N-methyl-D-aspartate receptor activation by the excitatory amino acid glutamate. 28 Marginal effects on cortical injury by progesterone may be related to differences in regional expression of GABA, glutamate, and progesterone receptor subunits/subtypes or to different ischemic mechanisms in the striatum versus the cortex.
Potential cooperation in stroke mechanisms between progesterone and estrogen must also be considered. From an endocrinological standpoint, it is well known that the background steroid environment of the brain alters the ability of progesterone or estrogen to alter reproductive signaling and behavior. 29, 30 Our previous work and that of others indicate that estrogen does not require normal plasma progesterone levels to reduce stroke injury. 2, 3, 8, [31] [32] [33] [34] However, estrogen priming is requisite for many progesterone-mediated actions in normal brain. 29, 30, 35 We also know that these 2 steroids interact at the receptor level, because estrogen, alone or in combination with progesterone, has been shown to upregulate progesterone receptor expression in brain. 36 Therefore, it may be that progesterone is most efficacious in an ischemic brain environment that has been estrogen primed.
These data have potential implications for clinical progestincontaining hormone replacement regimens and for an understanding of the relative importance of female sex steroids in stroke. It is currently uncertain whether combined estrogenprogestin therapy constitutes major cerebrovascular risks or benefits for women. Furthermore, unlike the estrogens, potential neuroprotective properties of progesterone have not been well investigated in cerebral ischemia or vascular disease in women.
Although cardioprotection has been reported with postmenopausal estrogen or estrogen-progestin replacement, 37,38 a limited number of epidemiological studies have evaluated progestins 39 and stroke risk in humans.
In conclusion, we have demonstrated that in contrast to the protection against ischemic injury observed in estrogentreated ovariectomized animals, chronic progesterone therapy before ischemia at pharmacological doses exacerbates ischemic striatal injury in ovariectomized female rats. The mechanism remains to be determined, and further studies are required to define dose-response relationships in experimental stroke.
